PTOSB26 (09-06) Approved for use through 03/01/2007. ONE 0551-031

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMENCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless fidigipays a wild ONE control number.

TERMINAL DISCLAIMER TO OBVIATE A DOUBLE PATENTING.

1 Docket Number Ordination.

REJECTION OVER A "PRIOR" PATENT	34370/US/4	
In re Application of: SEMPLE et al.		
Application No.: 10/658,947		
Filed: September 9, 2003		
For: High Efficiency Encapsulation of Charged Therapeutic Agents in Lipid Vesicles		
The owner*, The Lipiceraliz of British Columbia of 100 percent interest in the instant application hereby disclaims, except as provided below, the terminal part of the statutory term of any patient granted on the instant application which would extend below the expiration date of the full statutory term prior patient No. 6,258.225 as the term of said prior patient is presently shortened by any terminal disclaimer. The owner hereby agrees that any patient so granted on the instant application shall be enforceable only for and during such period that it and the prior patient are commonly owned. This agreement runs with any patent granted on the instant application shall be enforceable on for and unique such period that it and the prior patent are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns. In making the above disclaimer, the owner does not disclaim the terminal part of the term of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 and 173 of the prior patent, "as the term of said prior patent is presently shortened by any terminal disclaimer," in the event that said prior patent is presently shortened by any terminal disclaimer, in the event that said prior patent is prior patent in the prior patent, as the term of said prior patent is presently disclaimed in whole or terminally disclaimed under 37 CFR 1.321; has all claims canceled by a reexamination certificate; is reasoved, or		
Check either box 1 or 2 below, if appropriate.		
 For submissions on behalf of a business/organization (e.g., corporation, partnership, university, government agency, etc.), the undersigned is empowered to act on behalf of the business/organization. 		
I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or improsoment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.		
2. The undersigned is an attorney or agent of record. Reg. No. 39,754		
A		
Standard	January 22, 2007 Date	
Signature	Date	
Todd A. Lorenz		
Typed or printed name		
	(415) 781-1989	
	Telephone Number	
Terminal disclaimer fee under 37 CFR 1.20(d) included.		
WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.		
"Statement under 37 CFR 3.73(b) is required if terminal disclaimer is signed by the assignee (owner). Form PTO/SB/96 may be used for making this certification. See MPEP § 324.		
This Collection of Information is required to obtain or retain a benefit by the public with one of the public with ordinary or		

on the amount of unity you require to complete this form amon's suggestions for reducing this patient, should be sent wind enter imminished formers, P.O. Box 1450, Alexandria, V.2.2313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patients, P.O. Box 1450, Alexandria, V.4.22313-1450.

PTO/SB/26 (09-06)

Approved for use through 03/31/2007. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE ersons are required to respond to a collection of information unless it displays a valid OMB control number.

TERMINAL	DISCLAIMER TO OBVIATE A DOUBLE PATENTING	Docket Number (Optional)
12(4)	REJECTION OVER A "PRIOR" PATENT	34370/US/4
In re Application of: SE	MPLE et al.	
Application No.: 10/658	,947	
Filed: September 9, 200	03	
For: High Efficiency En	capsulation of Charged Therapeutic Agents in Lipid Vesicles	
except as provided belo the expiration date of th and 173, and as the ter granted on the instant a	ow, the terminal part of the statutory term of any patent granted on the instant	prior patent is defined in 35 U.S.C. 154 wener hereby agrees that any patent so prior patent are commonly owned. This
would extend to the exp patent is presently shor expires for failure t is held unenforcea		t granted on the instant application that prior patent, "as the term of said prior
is statutorily disclat has all claims cand is reissued; or	a court of competent jurisdiction; imed in whole or terminally disclaimed under 37 CFR 1.321; beled by a reexamination certificate;	
is in any manner to	erminated prior to the expiration of its full statutory term as presently shortened by	by any terminal disclaimer.
Check either box 1 or 2	below, if appropriate.	
For submission etc.), the under	ns on behalf of a business/organization (e.g., corporation, partnership, university rsigned is empowered to act on behalf of the business/organization.	, government agency,
belief are believed to b made are punishable b	re that all statements made herein of my own knowledge are true and that a e true; and further that these statements were made with the knowledge that y fine or impirsonment, or both, under Section 1001 of Title 18 of the United tize the validity of the application or any patent issued thereon.	willful false statements and the like so
2. The undersign	ned is an attorney or agent of record. Reg. No. 39,754	
		January 22, 2007
	Signature	Date
	Todd A. Lorenz	
	Typed or printed name	-
		(415) 781-1989
		Telephone Number
✓ Terminal disc	claimer fee under 37 CFR 1.20(d) included.	
W	/ARNING: Information on this form may become public. Credit card inform e included on this form. Provide credit card information and authorization	ation should not on PTO-2038.
*Statement under 37 C Form PTO/SB/96 may b	FR 3.73(b) is required if terminal disclaimer is signed by the assignee (owner). be used for making this certification. See MPEP § 324.	

This collection of information is required by 37 CFR 1.321. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiatly is governed by 35 U.S.C. 12.2 and 37 CFR 1.11 and 1.14. This collection is estimated to bake 12 minutes to complete to process of the confidentiation of the